LCAR-B38M CAR-T cell therapy

Drug Profile

LCAR-B38M CAR-T cell therapy

Alternative Names: CAR-T cell therapy - Nanjing; LCAR-B38M

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator Nanjing Legend Biotech
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 16 Feb 2017 Nanjing Legend Biotech has worldwide patent protection for LCAR-B38M CAR-T cell therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top